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Intracranial atherosclerosis is considered a cause of approximately 8% of all strokes in the western society. 
However, its frequency is much higher in Asian countries. In our hospital-based study, among the patients who had 
angiographic abnormalities, the frequency of intracranial atherosclerosis was approximately 70% far exceeding that 
of extratracranial atherosclerosis. Symptomatic atherosclerotic diseases were most often found in the middle cerebral 
artery. Generally, it has been shown that obesity and hyperlipidemia are related to extracranial diseases while 
advance hypertension is associated with intracranial diseases. However, these results have not always been 
replicated, and certain genetic factors may be related with the ethnic differences in the location of atherosclerosis. 
Recent studies using diffusion weighted MRI showed that the main mechanisms of stroke in patients with intracranial 
atherosclerosis are the branch occlusion, artery to artery embolism and both. The intracranial stenosis, especially 
symptomatic one, is not a static condition and may progress or regress in a relatively short period of time. 
Progressive stenosis of intracranial arteries is clearly related to the development of ischemic events. The annual risk 
of stroke relevant to the stenosed intracranial vessel is approximately 8 %. In retrospective studies including WASID, 
anticoagulation was found to be superior to aspirin in reducing the stroke events. However, a recent prospective 
study failed to confirm the superiority of anticoagulation over aspirin in patients with intracranial stenosis. Moreover, 
anticoagulation resulted in excessive central nervous system bleeding as compared to aspirin. Because aspirin alone 
seems to be insufficient in the prevention of progression of intracranial stenosis, a combination of antiplatelets has 
been tried. Recently, we found that a combination of aspirin ＋ cilostazol was superior to aspirin monotherapy in the 
prevention of progression of symptomatic intracranial stenosis. However, further studies are required to find out the 
best combination of antiplatelets for symptomatic intracranial stenosis. The effect of other atheroma stabilizers such 
as statins should also be properly evaluated. Angioplasty/stent is another important option for the relatively severe 
intracranial stenosis. According to previous studies, immediate success rate has reached up to 90%. If patients are 
carefully selected, and procedures done by experienced hand, angioplasty/stent can be of benefit especially in 
relatively young patients with proximal, short-segment, severe symptomatic stenosis. However, this procedure is not 
without complications or long-term re-stenosis. Further studies are required to elucidate the best therapeutic 
strategy in patients with intracranial atherosclerosis.
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INCIDENCE AND RISK FACTORS 
Intracranial atherosclerosis (IAS) has been shown to 
be an uncommon cause of stroke in western society 
occurring in approximately 8% of patients with ischemic 
stroke or transient ischemic attack.
1 This is especially a 
rare occurrence among Caucasians; according to the 
Northern Manhattan Stroke Study, only 1% of white 
patients suffered a stroke that was caused by an IAS.




7 studies have 
shown that the prevalence of IAS is much higher in 
Blacks and Asians. Moreover, because lacune-like small 
subcortical infarction can be caused by IAS,
8 and this 
may be regarded as a small vessel disease unless 
angiogram is routinely used, the prevalence of IAS is 
likely to be underestimated. In our institute, where 
approximately 90% of admitted patients underwent 
angiogram (mostly, MR angiogram), IAS is more 
common than extracranial atherosclerosis with an 
approximate ratio of 7:3. Symptomatic atherosclerosis 
most often occurred in the middle cerebral artery (MCA) 
(38%) which was followed by internal carotid artery 
(28%, extracranial carotid artery disease in 15%). 
The risk factors for IAS include hypertension, 
diabetes mellitus, cigarette smoking and hyperlipidemia. 
There have been debates about possible differences in 
risk factors between intracranial and extracranial 
diseases. Advanced hypertension has been shown to be 
a risk factor preferentially related to the former, while 
obesity and hyperlipidemia were regarded as important 
factors related to the latter.
9 However, our previous 
study failed to find differences in risk factors between 
intracranial and extranial atherosclerosis.
10 Inzitari et al 
also found that ethnicity was still a significant factor 
determining the site of atherosclerosis after adjusting 
various risk factors.
11 Perhaps, differences in certain 
genetic predisposition or morphological characteristics of 
the cerebral vessels may explain the difference in the 
incidence of IAS among different ethnicities.
DIAGNOSIS
For the diagnosis of IAS, conventional angiogram, 
MR angiogram (MRA), CT angiogram (CTA), and 
transcranial dopper (TCD) are widely used. Studies 
comparing MRA, CTA or TCD with catheter angio-
graphy have shown fairly high diagnostic sensitivity 
and specificity.
12,13 However, there has been no standard 
method for measuring the severity of IAS because 
established methods for measuring extracranial carotid 
stenosis may not be suitable for the IAS. Recently, a 
standardized method for measuring IAS was developed 
for Warfarin-Aspirin Symptomatic Intracranial Disease 
(WASID) trial.
14 Based on WASID measurement 
criteria, percent stenosis was defined as [(1-(Dstenosis/ 
Dnormal))]X100, where Dstenosis = the diameter of the artery 
at the site of the most severe stenosis and Dnormal =t h e  
diameter of the proximal normal artery. If the proximal 
segment was diseased, the contingency sites were chosen 
to measure Dnormal: distal artery (second choice) or 
feeding artery (third choice). This method showed good 
interobserver and intraobserver agreements. 
The diagnosis of IAS is sometimes challenging, 
particularly during the early post-stroke period. In this 
stage, it is difficult to differentiate intrinsic athero-
sclerotic disease from an embolic occlusion. In most 
previous studies including WASID trial,
15 IAS was 
diagnosed if there was stenosis more than 50% or 
occlusion without the presence of cardioembolic sources. 
However, complete cardiac work-up cannot be 
performed in all stroke patients. Moreover, cardio-
embolic mechanism cannot be completely excluded even 
if there is no definite abnormality in cardiac evaluation. 
In our preliminary data, among 53 patients with acutely 
diagnosed IAS (>50% or occlusion) detected by MRA, 
significant recanalization was achieved in 20 patients on 
follow-up MRA performed within a week of stroke 
onset. However, embolic sources from the heart or 
proximal arteries were not identified in 6 of those 20 
patients. Our data suggest that IAS may be over-
estimated in the acute stage and that follow-up vascular 
investigation is necessary for the proper evaluation of 
IAS.
It is well known that plaque vulnerability is more 
important than the degree of stenosis in the evolution of 
myocardial infarction. Therefore, it is not uncommon to 
see the development of myocardial infarction in patients 
with only mild or moderate coronary stenosis.
16 
Although it is still unclear whether coronary-like plaque 
rupture occurs in the IAS, there has been suggestion that 
similar phenomenon occurs in the IAS as well.
17 
Nevertheless, current imaging modalities have limitations 
in the identification of plaque characteristics of IAS. 
Moreover, an intact lumen observed by angiogram 
studies does not always indicate the absence of IAS. 
Future novel imaging techniques such as high resolution Kim JS, et al. Intracranial Atherosclerosis: Incidence, Diagnosis and Treatment 
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MRI may reveal atherosclerotic wall changes that do not 
make luminal stenosis.
18
PATHOLOGY AND STROKE MECHANISMS
Pathological studies on the IAS have been rare. The 
progression of atherosclerosis includes the stage of a 
fatty streak and that of a fibrous plaque. There has been 
suggestion that plaque morphology rather than the 
degree of stenosis may be more important in clinical 
events. The rupture of the unstable plaque, which is a 
large lipid core and a thin fibrous cap with evidence of 
inflammation, may cause the subsequent thrombosis and 
the ischemic stroke in patients with IAS.
17 
The lesion patterns and stroke mechanism caused by 
IAS are also understudied. In a recent study using 
diffusion weighted MRI (DWI) and TCD in 30 acute 
stroke patients with MCA stenosis, common stroke 
mechanisms were the occlusion of a single penetrating 
artery to produce a small subcortical lacune-like infarct 
or artery-to-artery embolism to produce multiple cerebral 
infarcts.
19 The authors also found that the number of 
microembolic signals predicted the number of acute 
infarcts detected on DWI. A high frequency (50%) of 
multiple acute infarcts on DWI in their study suggests 
that embolism is a common underlying mechanism in 
patients with MCA stenosis. Microembolism in cortical 
branches distal to MCA stenosis was also documented 
histopathologically.
20 
A single, small subcortical perforator infarct is also 
common in MCA stenosis. In these patients, the 
atheroma in the MCA seems to occlude the origin of a 
penetrating artery leading to a lacune-like infarct.
21 In 
our recent study using DWI and MRA, there was no 
difference in the lesion size between the subcortical 
lesions associated with MCA disease and those without. 
Therefore, the 1.5 cm size criteria for `small vessel 
disease򰡑  may be no longer valid.
22 According to our 
data, there also was no difference in clinical features 
between the two groups. However, another recent study 
suggested that small, deep infarcts associated with 
atherosclerotic MCA disease are related with unstable 
clinical courses.
23 The rate of stroke recurrence in 
patients with a parent arterial lesion may also be higher 
than that in those with small artery disease.
8
According to our data using DWI performed within 
48 hours of onset in 66 patients with MCA disease,
24 the 
most common lesion pattern was multiple infarcts 
involving both perforator and pial territories (n = 22), 
which were followed by single small (<2 cm) perforator 
infarct (n = 12). Our data suggest that thrombotic and 
embolic mechanisms frequently coexist in the patho-
genesis of infarcts in patients with atherosclerotic MCA 
disease. 
NATURAL COURSE
Previous studies have shown that IAS is a dynamic 
process with frequent progression or regression. In a 
retrospective study of 21 patients with 45 IAS, who 
underwent repeated angiography at an average interval 
of 26.7 months, intracranial internal carotid artery was 
relatively stable (20% progressed, 14% regressed) while 
stenosis occurring in the MCA, ACA or PCA was 
unstable (61% progressed, 28% regressed).
25 Another 
study reported that among 40 MCA stenosis, 33% 
progressed and 7.5% regressed during 26.6 months of 
follow up.
26 According to our results, the progression of 
symptomatic MCA stenoses (17/82, 20.7%) was more 
frequent than that of asymptomatic ones (3/60, 5%).
27 
Moreover, the progression of MCA stenosis was an 
independent predictor for clinical stroke recurrence.26 
Therefore, symptomatic IAS requires more aggressive 
therapeutic intervention than asymptomatic one. 
The natural course of IAS is likely to be influenced 
by risk factor modification. In addition, there has been 
suggestion that certain inflammatory or angiogenic 
factors are related to the natural course. A previous 
study showed that C-reactive protein (CRP), an 
inflammatory marker, was an independent factor for the 
progression of IAS as well as clinical recurrence.
28 A 
more recent study
29 measured the blood level of 
pro-angiogenic vascular endothelial growth factor 
(VEGF) and the anti-angiogenic endostatin in patients 
with symptomatic IAS. The authors attempted to see 
whether the levels of these proteins were related to the Journal of Clinical Neurology: Vol. 1, No. 1, 2005
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extent of IAS and the risk of stroke recurrence. They 
found that endostatin/VEGF ratio was independently 
associated with a greater extent of IAS. A higher level 
of endostatin was also a predictor for new stroke events. 
These results suggest that a predominance of the 
angiogenic inhibitor endostatin is associated with a 
greater extent of IAS and a higher risk of stroke 
recurrence in patients with symptomatic IAS.
MANAGEMENT
Based on the retrospective results suggesting the 
advantage of warfarin over antiplatelet agents,
30 a 
prospective WASID trial was performed. The study 
compared the efficacy of warfarin (INR 2-3) with that 
of aspirin (1300 mg/day) for preventing stroke and 
vascular death in patients with significant (more than 
50%) symptomatic IAS. This WASID trial was 
prematurely terminated by the NINDS following the 
recommendation of the Safety Monitoring Committee 
because of higher hemorrhagic rates than expected in the 
warfarin arm.
31 Although this trial attempted to show a 
30% risk reduction of warfarin against aspirin, it showed 
only a slight trend favoring warfarin at about 1.7 years 
of follow-up. Moreover, according to the Warfarin 
Aspirin Recurrent Stroke Study (WARSS) which 
recruited 2206 patients,
32 149 patients (13.5%) in the 
warfarin arm developed recurrent ischemic stroke, while 
123 (11.2%) in the aspirin arm developed strokes at 
about 2.1 years of follow up. For large artery stroke, the 
primary events (death or recurrent ischemic stroke) 
occurred more often in patients on the warfarin (18.7%) 
than those on the aspirin (15.6%). Therefore, oral 
anticoagulation is nowadays not recommended in 
patients with symptomatic IAS. Nevertheless, there still 
is a lingering argument that using anticoagulation in the 
early stage of stroke may be beneficial especially in 
patients with a presumed high risk of recurrence. 
According to the EC-IC bypass trial, the annual risk 
of stroke in the aspirin arm was unacceptably high in 
patients with IAS reaching to 7.7-9.5%.
33 Therefore, a 
combination of antiplatelet agents with different 
mechanism of action has been considered. The 
synergistic effect was indeed present when aspirin (a 
cyclo-oxygenase inhibitor) and clopidogrel (inhibitor of 
ADP-induced platelet aggregation) were combined in 
patients with acute coronary syndrome34 or in those 
who underwent percutaneous coronary intervention.
35
European Stroke Prevention Study 2 (ESPS-2) 
revealed that a combination of aspirin (a cyclo- 
oxygenase inhibitor) and dipyridamol (phosphodiesterase 
inhibitor) was significantly more effective than when 
either agent was prescribed singly in the secondary 
prevention of stroke.
36 However, it remains unknown 
whether this combination is superior to monotherapy in 
patients with IAS. Moreover, recent studies have 
suggested that two is not always better than one. 
MATCH (Management of ATherothrombosis with 
Clopidogrel in High-risk patients) was a trial expected 
to show a beneficial effect of the combination of aspirin 
and clopidogrel over clopidogrel monotherapy in patients 
with ischemic stroke. In this trial, adding aspirin only 
slightly (insignificantly) reduced the incidence of 
ischemic stroke, myocardial ischemia, or vascular death. 
Furthermore, the benefit was offset by life threatening 
hemorrhages into the gastrointestinal tract or brain in 
patients with combined treatment.
37 The unexpected 
results may be related with the inclusion of unusually 
large proportion of lacunar strokes; it has been shown 
that lacunar infarction is related to a relatively high risk 
of subsequent intracerebral hemorrhage, and a low risk 
of recurrent stroke as compared to those with stroke due 
to large vessel atherosclerosis. Therefore, it remains 
unclear whether the combination of aspirin and 
clopidogrel is superior to aspirin or clopidogrel 
monotherapy in patients with IAS.
Recently, we have considered combining aspirin with 
cilostazol, a phosphodiesterase III inhibitor. Cilostazol 
has an antipletelet as well as vasodilating effects, and 
has been shown to be effective in the symptomatic 
improvement for the intermittent claudication
38 and in 
the prevention of restenosis after coronary angioplasty 
and stenting.
39 In our trial, we studied 135 patients with 
acute symptomatic IAS. The patients were randomly 
treated with either cilostazol 200 mg a day or placebo 
for 6 months. Aspirin 100 mg per day was also given 
to all patients. MRA and TCD were performed at <2 Kim JS, et al. Intracranial Atherosclerosis: Incidence, Diagnosis and Treatment 
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weeks and at 6 months after stroke onset, and the 
change of the initial stenosis was assessed. In the aspirin
＋cilostazol group, IAS progressed in 3 and regressed 
in 11 out of 45 arteries whereas in the aspirin group, it 
progressed in 15 and regressed in 8 out of 52 arteries. 
The progression rate of symptomatic IAS was 
significantly lower in the ciostazol+aspirin than in 
aspirin monotherapy group (p=0.018).
40 Because of the 
short term follow up, we were not able to see the actual 
reduction of clinical events by the combined treatment. 
However, considering previous results that the 
progression of IAS is related to clinical recurrence
26,41 
the combined treatment seems to be of benefit in the 
reducing the recurrence of ischemic strokes as well. 
Nevertheless, we do not know whether the aspirin ＋
cilostazol combination is superior to other types of 
combination. In addition, there still are other drugs that 
may be beneficial in patients with IAS. In a recent trial, 
there was a tendency of the less progression of IAS in 
patients who received statin as compared to those 
receiving a placebo. However, this did not reach to a 
statistical significance. Instead, statin use was effective 
in reducing the development of white matter signal 
intensities detected by MRI.
42 Therefore, further studies 
are required to elucidate what is the best medical 
treatment for the IAS. 
The IAS may be managed by non-medical ways of 
treatment. Percutaneous transluminal angioplasty and 
stenting (PTA) for the IAS should be considered as a 
complementary treatment to reduce the risk of ischemic 
stroke. We personally experienced that intractable TIAs 
improved after the PTA. However, because there have 
been no randomized clinical trials to prove its benefit, 
PTA should be carefully performed in appropriately 
selected patients. Technical successful rates of the 
reported cases were usually high (85-98%), but the 
complication of the PTA is not uncommon (10-33%).
43-46 
Urgent PTA is related with even higher major 
neurological complication (50%) and mortality rate 
(16.7%).
47 The results of Stenting of Symptomatic 
Atherosclerotic Lesions in the Vertebral or Intracranial 
Arteries (SSYLVIA)
48 were more promising than 
previous reports. The procedure-related stroke rate was 
very low (6.6%) and technical successful rate was fairly 
high (95%). However, restenosis rate was high (32.4%), 
which was related with relatively frequent (39%) clinical 
events. Currently, we consider PTA for IAS in patients 
with symptomatic, medically intractable, technically 
feasible (proximal, short segment) and severe (>50%) 
IAS. In our experiences with 35 symptomatic patients, 
angiographic success rate was 97% and there were four 
procedure-related complications (11%) including a death 
and a minor stroke. During the average of 22 months 
follow up, restenosis occurred in five (15%) in the target 
vessels (symptomatic in 2, and asymptomatic in 3).
49 
More researches are required to improve the results of 
PTA. 
Finally, extracranial-intracranial artery bypass surgery 
is another option for the severely stenosed or occluded 
intracranial arteries. Although previous EC-IC bypass 
trial failed to show any benefits,
33 this procedure may 
still be of value in highly selected patients. Considering 
the results of the Japanese EC-IC bypass trial,
50 bypass 
surgery may help the patients with symptomatic IAS 
associated with hemodynamically compromised status.
51
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